A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs TTP 399 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Simplici-T1; SimpliciT1
- Sponsors vTv Therapeutics LLC
- 16 Jan 2019 According to a vTv Therapeutics LLC media release, results from part 1 of the study are expected later this year.
- 31 Aug 2018 Biomarkers information updated
- 22 Jun 2018 According to a vTv Therapeutics media release, phase II portion of this trial is ongoing.